The novel RORγt inverse agonist and TGR5 agonist compound 7 (University of Naples) has been shown to provide robust anti-inflammatory activity in mice models of TNBS-induced colitis, reducing TNFα, IL-1β, and IL-6 expression while increasing IL-10 and TGFβ expression. The gene discussed is TNF; the disease is colitis.